Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
1(13%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
2
25%
Ph phase_2
6
75%

Phase Distribution

0

Early Stage

6

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
6(75.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)
Other(2)

Detailed Status

Completed4
Recruiting1
Terminated1
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 26 (75.0%)
Phase 32 (25.0%)

Trials by Status

completed450%
recruiting113%
terminated113%
suspended113%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_2

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941
suspendedphase_2

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

NCT05062889
completedphase_2

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

NCT04513951
completedphase_2

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

NCT03721653
completedphase_3

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

NCT03231722
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06219941Phase 2

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Recruiting
NCT05062889Phase 2

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Suspended
NCT04513951Phase 2

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Completed
NCT03721653Phase 2

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Completed
NCT03231722Phase 3

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Completed
NCT02904031Phase 2

Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients

Unknown
NCT00005586Phase 3

Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

Completed
NCT00209703Phase 2

Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8